Following profitable scientific trials for its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, Sirona Biochem (TSXV:SBM) is pursuing a path to commercialization for a ultimate beauty product, in line with the corporate’s chief scientific officer, Géraldine Deliencourt-Godefroy.
“We’re nonetheless pursuing a ultimate compound to launch available on the market, which is fairly good as a result of it should permit us to have a greater management on the ultimate product. We will launch quick available on the market, we will generate income earlier and in addition the extent of income shall be larger,” Deliencourt-Godefroy mentioned.
Sirona has already trademarked its anti-aging skincare ingredient, GlycoProteMim, as one of many first steps for commercialization. In January of this 12 months, the corporate additionally launched a brand new cosmetics subsidiary, Sirona Laboratories, which is devoted to maximizing the business potential of GlycoProteMim.
“We have now accomplished the method growth, and we are actually in a position to scale up (the compound) for any amount,” defined Deliencourt-Godefroy. She mentioned the corporate is presently growing a premium formulation for the ultimate beauty product, and is working with a beauty model designer and different groups wanted to construct and market the product.
The corporate plans to launch the product in early 2025, starting within the US and Canadian markets and finally introducing it within the European market. The product shall be made in France, Deliencourt-Godefroy mentioned.
Watch the total interview with Géraldine Deliencourt-Godefroy, chief scientific officer of Sirona Biochem, above.
Disclaimer: This interview is sponsored by Sirona Biochem (TSXV:SBM). This interview supplies info which was sourced by the Investing Information Community (INN) and authorized by Sirona Biochem in an effort to assist buyers study extra in regards to the firm. Sirona Biochem is a consumer of INN. The corporate’s marketing campaign charges pay for INN to create and replace this interview.
INN doesn’t present funding recommendation and the data on this profile shouldn’t be thought-about a suggestion to purchase or promote any safety. INN doesn’t endorse or advocate the enterprise, merchandise, companies or securities of any firm profiled.
The data contained right here is for info functions solely and isn’t to be construed as a proposal or solicitation for the sale or buy of securities. Readers ought to conduct their very own analysis for all info publicly obtainable in regards to the firm. Prior to creating any funding choice, it is suggested that readers seek the advice of instantly with Sirona Biochem and search recommendation from a professional funding advisor.
This interview could include forward-looking statements together with however not restricted to feedback relating to the timing and content material of upcoming work applications, receipt of property titles, and many others. Ahead-looking statements tackle future occasions and circumstances and due to this fact contain inherent dangers and uncertainties. Precise outcomes could differ materially from these presently anticipated in such statements. The issuer depends upon litigation safety for forward-looking statements. Investing in corporations comes with uncertainties as market values can fluctuate.
